Podcast appearances and mentions of neil clark

A (relatively) in-depth analysis of English singer-songwriter Lloyd Cole in under thirty minutes.Cole was the lead vocalist of Lloyd Cole and the Commotions from 1984 to 1989. Since then he has enjoyed a prolific solo career with his first album 'Lloyd Cole' being released in 1990.'Downtown' from his first album was featured in the 1990 film Bad Influence. 'Pay for It' from Cole's 1991 album 'Don't Get Weird on Me Babe' was also featured on the soundtrack of When the Party's Over. In 2023, Cole released his twelfth album 'On Pain', featuring songs recorded in his attic (which brings to mind the first line of the 1982 Adrian Gurvitz hit 'Classic). Four of the songs on the 'On Pain' album were co-written by founding Commotions members Blair Cowan and Neil Clark.Cole is now based in Easthampton, Massachusetts.In this episode I am in discussion with Dr. Andrew Webber.Mathew Woodallhttps://buymeacoffee.com/lownoiseWhy buy me a coffee?Low Noise is proudly ad-free. If you would like to to say thank you for any of the content you have enjoyed (and help support the continuation of creating more), the above link provides a way to make a small donation of your choice (I also function on coffee!).Feel free to leave a note with your donation to let me know what you enjoy about the podcast or any topics you would like me to discuss in the future.

The Feeling Sound Podcast Season Three - Episode Five Raised in Glasgow and now living in the city of Toronto, guitarist Neil Clark played with many bands in his original home city, including Newspeak with Alan McGee and Andrew Innes, before meeting Lloyd Cole and Blair Cowan, with the three forming the nucleus of Lloyd Cole and the Commotions.  They recorded three studio albums, Rattlesnakes, Easy Pieces and Mainstream, and Neil was co-writer of some of the groups best-known songs - Are You Ready To Be Heartbroken, Rattlesnakes and Lost Weekend, while also playing the multi-layered guitar coda to Forest Fire.  He has remained a regular collaborator with Lloyd Cole over the years, including contributions to his past two albums Guesswork and On Pain. In addition to his work with Cole, he has recorded with many other artists internationally. Recent projects include Lake and Sea with singer Theresa McKay, post-jazz trio Clark, Jones and Pottie and the solo album, Sundogs.- all of which can be found at neilclark.bandcamp.com. We caught up with Neil at his Toronto home, where we talked about his incredible musical journey, the stories behind some of the tunes that make up the phenomenal Commotion's back catalogue, touring … and above all else, what music means to him.

Lloyd Cole with Ian Blackley  Australia's love affair with the UK's icon of literate pop, Lloyd Cole, continues when he returns to these shores following his 2019 sold out tour. Lloyd will tour to support his newly released album On Pain which features eight new original tracks, four of which are co-written by founding Commotions members Blair Cowan and Neil Clark, who also perform on the record. For this Australian tour Lloyd will be performing a mix of his newest music along with old favs.See omnystudio.com/listener for privacy information.

In today's episode, we continue reviewing the book by Neil Clark. Warren called The Triumphant Marriage by addressing Secret #3: Maximize the Trust Factor. --- Send in a voice message: https://podcasters.spotify.com/pod/show/larry-quicksall/message

This week: James Heale reads his politics column on why the Tories should fear the Greens (00:56), Lisa Haseldine outlines some of the changes to Russia's school curriculum (06:04) and Neil Clark extols the joys of non-league football (13:02).   Produced and presented by Oscar Edmondson. 

This week: James Heale reads his politics column on why the Tories should fear the Greens (00:56), Lisa Haseldine outlines some of the changes to Russia's school curriculum (06:04) and Neil Clark extols the joys of non-league football (13:02).   Produced and presented by Oscar Edmondson. 

Political reporters Laura Bischoff and Jessie Balmert speak with Jeff Williams, former FBI agent on the latest special edition of the Ohio Politics Explained podcast. During this episode we discuss the news splash that the Householder arrest made and the role that super lobbyist Neil Clark played in the largest public correct case in Ohio history.

Neil Clark, CEO of Destiny Pharma #DEST describes how SPOR-COV® showed positive results from testing in several COVID-19 and influenza research models, which support potential as prophylactic nasal spray. Also a Phase 1 clinical studies has been completed successfully in Vietnam by HURO and a retail product has been launched there meaning Destiny could be due future royalty payments. Highlights of the data from these studies show: 1.   Prophylaxis of COVID-19 observed in SARS‑CoV‑2 preclinical challenge models. 2.   Significant reduction in signs and symptoms of influenza across multiple preclinical models, including a gold-standard model of influenza infection in "Vaccines" journal (James et al., 2022). Studies were conducted across several investigative sites. 3.   SPOR-COV nasal spray use as a potential adjunct/booster to existing vaccines is supported by preliminary immunological research. 4.   Technical development programme lead by HURO has been successful and enabled a scalable manufacturing process for GMP material. 5.   GLP preclinical safety studies successfully completed and therapeutic window supportive of clinical development defined. About SPOR-COV SPOR‑COV product consists of a proprietary formulation of Bacillus bacteria that is administered nasally as a spray. Importantly, this product is completely sterile and poses no risk of administering live bacteria. SPOR-COV is different to traditional vaccines in that it utilises the innate immune system with the aim of developing COVID-19 and influenza protection alone or possibly in combination with vaccine therapies a few days after dosing. As an "easy to use" product, for COVID-19 and influenza it has the potential to significantly reduce both infection rates and transmission. The final SPOR-COV product is planned to be straightforward to produce at high volumes and at low cost. Additional attributes are that (i) it can be stockpiled almost indefinitely without the need for cold chain logistics as it is a particularly stable product, (ii) made available globally as a cost-effective measure in the fight against COVID-19 as well as new COVID variants, and (iii) potential efficacy against other respiratory viral infections."  To read the full RNS click here

Neil Clark, CEO & Shaun Claydon, CFO of Destiny Pharma #DEST discuss their final results & post period highlights, which included a deal on their lead asset, NTCD-M3, worth up to $570m plus royalties. Neil also points out that the number one target for the company this year is landing a deal on their second late stage asset, XF-73. Highlights - Exclusive North American partnering deal worth up to $570m plus royalties secured for NTCD-M3 - Phase 3 development plans finalised for XF-73 nasal following scientific advice from FDA and EMA - XF-73 dermal commenced clinically enabling safety study sponsored by US Government's NIAID - New XF research projects initiated in cystic fibrosis and oral mucositis - Leadership strengthened with appointment of Chief Medical Officer and two Non-Executive Directors - Balance sheet strengthened through £7.3 million fundraise post period end To read the full RNS click here

Neil Clark, CEO of Destiny Pharma #DEST discusses XF-73's Phase 2 data published in peer reviewed journal and the potential upside for the share price. Three brokers price targets currently stand at: Equity Development = 267p, Finncap = 285p, Shore Capital = 290p. Current share price = 31p. The paper was published by Dr. Julie Mangino (Professor Emeritus, Division of Infectious Diseases, at The Ohio State University, US) who is the lead author and a member of the Data Safety Monitoring Committee for the clinical trial. It highlights the following key results: ü Achieved the study primary endpoint: XF-73 showed a 99.5% reduction in S. aureus bacterial nasal carriage, which is a clinically relevant reduction in nasal carriage. This equates to a reduced nasal burden of S. aureus in patients undergoing open heart surgery by 2.5 log (CFU/ml) in the 24 hours immediately before surgery, a highly statistically significant result, (p

Neil Clark, CEO & Shaun Claydon CFO of Destiny Pharma #DEST discuss their exclusive collaboration and co-development agreement for NTCD-M3 with Sebela Pharmaceuticals® which is worth up to $570m plus royalties & the equity fundraising of up to £8 million. Highlights Destiny Pharma is pleased to announce that it has signed an exclusive collaboration and co-development agreement for the North American rights of NTCD-M3, its lead asset for the prevention of Clostridioides difficile infection (CDI) recurrence, with Sebela Pharmaceuticals® , a U.S. pharmaceutical company with a market-leading position in gastroenterology. Under the terms of the deal, it is anticipated that Sebela will lead and finance the future clinical development and commercialisation activities of NTCD-M3 in North America. The Company retains the majority of rights for Europe and Rest of the World and Sebela has a minority interest in any income generated in these non-North American territories based on the clinical studies it is funding. The agreement, which could be worth up to $570m to Destiny Pharma in milestones alone, includes; - An initial upfront payment of $1m; - Success-based development milestones of $19m; - Sales revenues-based milestone payments up to $550m; and tiered, double-digit royalties. Destiny Pharma has the obligation to continue its current plan to complete the ongoing manufacture of all clinical trial supplies needed to undertake the required clinical studies. It is anticipated that Phase 3 studies will commence in 2024. To read the full RNS click here

On the podcast this week: How will the war on Ukraine end? This is the question that Russia correspondent Owen Matthews asks in his cover piece for The Spectator. He is joined by Rose Gottemoeller, former deputy secretary general of Nato, to discuss whether the end is in sight (01:02). Also this week: Matthew Parris interviews the theologian and ethicist Nigel Biggar on the legacy of Empire. They have kindly allowed us to hear an extract from their conversation, printed as a dialogue in this week's issue. They discuss Nigel's motivations for writing his controversial new book Colonialism: A Moral Reckoning, and reconsider the economics of colonialism (18:52). And finally:  Neil Clark writes that greyhound racing should not be banned, despite the news that the RSPCA has changed it position to oppose the sport. He is joined by Vanessa Hudson, leader of the Animal Welfare Party, to debate whether dog racing has had its day (29:03).  Hosted by William Moore.  Produced by Oscar Edmondson.

Tunes: Inveraray & District Pipeband: March, Strathspey & Reel Three on the Bund: Local Hero Simon Pfisterer: Vivaldi's Concerto for Four Violins in B minor Karel Westerling: Riding Free Spirit Brighde Chaimbeul, Ross Ainslie and Steven Byrnes: The Badger and the Weasel Glengervie: Sine Bhan/ Come by the Hills, Christ Has My Heart Aye/The Mermaid/In And Out The Harbour /Juan Martino's, The Lonesome Boatman Dave Rowlands: Chickadee, The Purturbation, Jim Harding's Waltz Nicholas Konradsen: Waltzish Set, Farewell to Gagnef, Smoke Braider's Bourree, Farewell to Claremont Falsobordone: Maria Unser Frowe, Quant j'ay l'espart, A tutta gente Jason Rouse: The Spanish Cloak, Job of Journey Work Rebel's Menuet: Mairi Bhan Òg (Mary young and fair), Bothan Airidh 'm Braighe Rainneach (The Shieling on the Braes of Rannoch), Drumochter Reels: (1) Calum Figheadair (“The Kilchattan Wedding”) / (2) Druimuachdar / (3) Uist Reel Inveraray & District Pipe Band A Night in that Land https://idpb.bandcamp.com/album/a-night-in-that-land March, Strathspey and Reel +X+X+X+X+ Three on the Bund & Simon Pfisterer Local Hero by Three On the Bund: https://3onthebund.bandcamp.com/album/frenzy Vivaldi's Concerto for Four Violins in B minor Simon Pfisterer's New Album, Another Way To Go Available for order here: https://simonpfisterer.com/shop/ +X+X+X+ Karel Westerling Riding Free Spirit: https://www.youtube.com/watch?v=EQBLqlMC3ME Check out Karel's Stellar Youtube page +X+X+X+ LAS LAS features: Brighde Chaimbeul - C Smallpipes Ross Ainslie - C Smallpipes Steven Byrnes - Guitar and Mandola The Badger and the Weasel https://brighdechaimbeul.bandcamp.com/album/las +X+X+X+X+ Glenbervie - Nae Borders Glenbervie is Neil Clark and Kathryn Grainger Sine Bhan/ Come by the Hills Christ Has My Heart Aye/The Mermaid/In And Out The Harbour /Juan Martino's The Lonesome Boatman https://glenbervie.bandcamp.com/album/nae-borders +X+X+X+ Dave Rowlands Original Compositions on Jon Swayne Low D pipes Chickadee The Purturbation Jim Harding's Waltz https://daverowlandsbagpipes.bandcamp.com/album/dave-rowlands-bagpipes +X+X+X+ Nicholas Konradsen The New Leaf Original Compositions by Nicholas, Plays Sweedish pipes of his own make and Jon Swayne Border Pipes Waltzish Set Farewell to Gagnef Smoke Braider's Bourree Farewell to Claremont https://nicholaskonradsen.bandcamp.com/album/the-new-leaf +X+X+X+ 1350 - Music for a plague by Falsobordone Falsobordone is: Falsobordone: Erik Ask-Upmark, Anna Rynefors With guests: Karin S Lagergren, Daniel Åhlman, Magne Pettersson, Shira Kammen, Daniel Serra Maria Unser Frowe, Quant j'ay l'espart A tutta gente https://erikaskupmark.bandcamp.com/album/1350-music-for-a-plague +X+X+X+ Jason Rouse: Fieldish Recordings Waltz: The Spanish Cloak Set Dance: Job of Journey Work https://pipingrouse.bandcamp.com/album/fieldish-recording +X+X+X+ Hessians & Highlanders 1746 in Scotland Music & story compiled & arranged by Quest Christian Tewordt Music performed by Duo “Rebel's Menuet” Johanna Wildhack & Quest Mairi Bhan Òg Bothan Airidh 'm Braighe Rainneach Drumochter Reels To get the Book/Album Combo order here: https://www.verlag-ralf-liebe.de/programm/262/hessen-highlander/ +X+X+X+ FIN Here are some ways you can support the show: You can support the Podcast by joining the Patreon page at https://www.patreon.com/wetootwaag You can also take a minute to leave a review of the podcast if you listen on Itunes! Tell your piping and history friends about the podcast! Checkout my Merch Store on Bagpipeswag: https://www.bagpipeswag.com/wetootwaag You can also support me by Buying my First Album on Bandcamp: https://jeremykingsbury.bandcamp.com/album/oyster-wives-rant-a-year-of-historic-tunes or my second album on Bandcamp! https://jeremykingsbury.bandcamp.com/album/pay-the-pipemaker or my third album on Bandcamp! https://jeremykingsbury.bandcamp.com/album/bannocks-of-barley-meal You can now buy physical CDs of my albums using this Kunaki link: https://kunaki.com/msales.asp?PublisherId=166528&pp=1 You can just send me an email at wetootwaag@gmail.com letting me know what you thought of the episode! Listener mail keeps me going! Finally I have some other support options here: https://www.wetootwaag.com/support Thanks! Listen on Itunes/Apple Podcasts: https://podcasts.apple.com/us/podcast/wetootwaags-bagpipe-and-history-podcast/id129776677 Listen on Spotify: https://open.spotify.com/show/5QxzqrSm0pu6v8y8pLsv5j?si=QLiG0L1pT1eu7B5_FDmgGA

1:45 Labiotech.eu news4:02 PsychoGenics20:56 Destiny Pharma36:30 QureTech Bio54:41 AiCuris70:45 JLLThis week, we have three interviews on the theme of antimicrobial resistance (AMR), to mark World Antimicrobial Awareness Week. We spoke with Holger Zimmermann, CEO of anti-infectives company AiCuris; Neil Clark, CEO of Destiny Pharma, and Fredrik Almqvist, co-founder of QureTech Bio.We also have an interview with the chief scientific officer at PsychoGenics, Mark Varney. We also have our weekly contribution from global commercial real estate services company JLL, with Travis McCready. Next week, we will be moderating a webinar on the microbiome, hosted by our sister company IN-PART. You can register here.World Antimicrobial Awareness WeekAs a result of drug resistance, antibiotics and other antimicrobial medicines may become ineffective and infections become increasingly difficult or impossible to treat. A global action plan to tackle the growing problem of resistance to antibiotics and other antimicrobial medicines was endorsed at the 68th World Health Assembly in 2015. A key objective of the plan is to improve awareness and understanding of AMR through effective communication, education and training.World Antimicrobial Awareness Week is a global campaign to improve awareness and understanding of AMR. Emyria commences US preclinical program with PsychoGenicsEmyria Limited, a clinical stage biotech, is working with PsychoGenics, a specialist neuroscience preclinical drug discovery and contract research organization (CRO). Emyria and partner, the University of Western Australia, will start by screening five novel MDMA analogs from their proprietary library using PsychoGenics' advanced drug discovery platform, SmartCube. SmartCube employs computer vision and artificial intelligence (AI) to extract and analyze behavioral and physiological data from mice. These data can help predict the clinical effects of new drug compounds by comparing the novel drug's effects to reference drug libraries. The automated testing platform offers an effective approach to the discovery and development of the next generation of breakthrough treatments for neurological disorders and can significantly reduce the time and cost to reaching approved Investigational New Drug status. PsychoGenics and Emyria have agreed to work collaboratively (at their own costs) in the initial phase, before exploring drug discovery and commercialization partnership models. PsychoGenics's specialist drug screening platforms have been used in shared-risk partnerships with major pharmaceutical companies, including Sunovion and Roche, resulting in the discovery of several novel compounds now in clinical trials or advanced preclinical development. A successful partnership with Emyria could accelerate the development of Emyria's novel MDMA-inspired drug candidate library, built with the University of Western Australia, into new treatments for severe neuropsychiatric disorders. PsychoGenics has successfully identified novel treatment candidates for serious and complex neuropsychiatric disorders via its proprietary SmartCube platform as well as formed innovative partnerships with major Pharmaceutical companies.SponsorInterested in sponsoring one or more episodes of the podcast? Learn more here!Leave a review on Apple podcastsReviews are hugely important because they help new people discover this podcast. If you enjoyed listening to this episode, we would love to hear your feedback!Connect with us

This is Bed Crime Stories - a weekly True Crime Podcast where your hosts pour themselves a drink and take turns telling one another the stories that keep them up at night!  In this new episode of Bed Crime Stories, Jovie tells us a listener story request about the murder of Allison Neil Clark who was found deceased in her car on the side of the road with her 3-year-old daughter, thankfully, unharmed in the backseat. True Crime and comedy... Sounds crazy, we know. We add humor to cope with the harsh reality of the stories we tell and alleviate some of the heaviness for our listeners. No one here at Bed Crime Stories are experts, just lifelong fans of all-things true crime. Music credit Industrial Music Box by Kevin MacLeod Link: https://incompetech.filmmusic.io/song/3910-industrial-music-box License: http://creativecommons.org/licenses/by/4.0/

Neil Clark CEO & Shaun Claydon, CFO of Destiny Pharma #DEST & reflect on the progress they have made on their late-stage clinical assets in H1 & are confident of further advancement toward major milestones in 2022 and beyond. Financial highlights · Cash and short term deposits at 30 June 2022 of £8.4 million (30 June 2021: £7.1 million; 31 December 2021: £4.6 million). · Net assets of £10.7 million at 30 June 2022 (30 June 2021: £10.2 million; 31 December 2021: £7.5 million). · Expenditure on R&D in the period of £2.5 million (half-year 2021: £2.0 million; full year 2021: £3.7 million). · Company funded through to mid-2023. Operational highlights NTCD-M3 for the prevention of C. difficile infection (CDI) recurrence · Finalising preparations for the pivotal Phase 3 clinical trial of NTCD-M3 and good progress made on partner discussions to help co-fund studies and lead commercialisation.   · Positive scientific advice received from European Medicines Agency (EMA) on proposed Phase 3 study design. · US and European market research confirms substantial market opportunity for NTCD-M3. · Results from US research support the use of NTCD-M3 following all commonly used antibiotic treatments. · Positive new data published on the absence of toxic gene transfer to NTCD-M3 in the peer-reviewed journal, Public Library of Science One (PLOS ONE). XF-73 Nasal for the prevention of post-surgical infections · US Food and Drug Administration (FDA) has clarified Phase 3 and US registration pathway for XF-73 Nasal gel for the prevention of post-surgical staphylococcal infections. · EMA feedback on XF-73 Nasal gel Phase 3 programme identifies a clear route through European approval as a ground-breaking hospital infection prevention product. · Global Phase 3 study design progressing following discussions with regulators and key opinion leaders. · External European market research reports show that XF-73 Nasal gel is seen as a very promising alternative to the current standard of treatment, mupirocin, by both clinicians and payers. The study suggests XF-73 has the potential to replace the current standard of treatment as the preferred pre-surgical nasal decolonisation agent. To read the full RNS click here

On this week's episode: Katy Balls has written about what foreign policy would look like under a Liz Truss government (0:54). Rachel Johnson believes we can all learn from the Lionesses' victory  (06:55) and Neil Clark shares Jim Corbett's tiger hunting stories  (12.23). Presented and produced by Natasha Feroze.

Destiny Pharma #DEST chief executive Neil Clark talks us through the publication of new data on NTCD-M3, its novel treatment for the prevention of C. difficile infection (CDI) recurrence, in the peer reviewed journal Public Library of Science One. C.difficile is the leading cause of hospital acquired infection in the US and current treatments lead to significant recurrence. In the US, there are approximately 500,000 cases of CDI each year, with many of these initial cases recurring leading to 29,000 deaths per year and costing the healthcare industry billions of dollars. The study - carried out by Destiny's scientific adviser Professor Dale Gerding and his team at the VA Hines laboratories in the US - offers further validation of the potential of the biotherapeutic ahead of planned Phase 3 clinical trials of NTCD-M3 in 2023 having previously reported very good Phase 2 clinical trial results. Destiny is currently finalising preparations for thel trial and seeking partners to help co-fund studies and lead commercialisation of this exciting biotherapeutic product. To read the full RNS click here.

Neil Clark, CEO of Destiny Pharma #DEST explains the positive update from US FDA, on their XF-73 nasal gel, that will enable simplification of the Phase 3 study design, which is expected to shorten the overall clinical development programme in the U.S. The key points from the FDA's feedback are: ·    The FDA agreed to the proposed Phase 3 design comparing XF-73 Nasal gel to placebo on top of standard of care for the prevention of post-surgical staphylococcal infections following certain breast surgery operations. This type of surgery is being proposed as patients can experience a relatively high infection rate following the current standard of care and there is a clear unmet medical need. ·    The FDA is open to the collection of microbiological data during the proposed Phase 3 study that could lead to the development of a surrogate marker for clinical efficacy in other types of surgery. ·  Based on the favourable safety profile from the clinical development programme so far, the FDA has confirmed that no specialised nasal examinations are needed in the Phase 3 study. In line with the above, the FDA has also removed the previous requirement to clinically evaluate skin sensitisation. ·    The regulatory feedback will enable Destiny Pharma to simplify the Phase 3 study design and is expected to shorten the overall clinical development programme in the US. To read full the RNS click here

Neil Clark, CEO of Destiny Pharma #DEST discusses the start of a new XF-73 research programme as a preventive medicine to alleviate suffering from Oral Mucositis in patients receiving cancer treatment by testing its efficacy in the gold-standard model of OM & also provides an update on the progress of their lead clinical assets. Highlights The potential utility of XF-73 in this indication is due to the long-recognised association between the development of OM and changes in the oral microbiome. The unique antimicrobial properties of XF‑73 have already been demonstrated in Phase 2 clinical trials. As well as having fast-acting antimicrobial activity and a novel mechanism of action, XF-73 has an excellent safety profile and a lack of systemic exposure which means that it is ideally suited for development as an innovative oral formulation to reduce the severity of OM. Inflammation of the mucosa (mucositis) is considered one of the most serious non-hematological complications of cancer treatment and a common dose-limiting complication of high-dose radiotherapy and chemotherapy in cancer and bone marrow transplant patients of all ages. Globally, more than two million cancer patients suffer from this condition each year. The global OM market was estimated at $2.2b in 2018. To read the full RNS click here

John Connolly, The Spectator's news editor, speaks to historian Anthony Seldon about whether Boris Johnson might resign: ‘Why on earth would he want to carry on and have more of this humiliation? Why wouldn't want to take the dignified path of saying: “I'm going to fall on my sword.”' On the rest of the show, Spectator contributor Owen Matthews and our Wild Life columnist Aidan Hartley discuss how far Putin is to blame for global food shortages, the Refugee Council's Enver Solomon says the Home Office is in crisis, and sports journalist Neil Clark explains why, despite the danger, the Isle of Man TT should be celebrated, not banned. Watch the full episode at: www.spectator.co.uk/tv

What influences your picture of what manhood should be? Is your view formed by magazines, movie icons, or culture? Join us today as Neil leads us in learning more about true manhood and how God defines it through His word.

Neil Clark, CEO & Dr Bill Love, Chief Scientific Officer of Destiny Pharma #DEST explain the significance of world leading C. difficile scientists presenting landmark data on the ability of NTCD-M3 (one of its clinical assets) to colonise the gut after antibiotic administration at the prestigious Anaerobe 2022 Conference in Seattle, WA, US on Saturday, 30th July 2022. Highlights As previously reported, a Phase 2 clinical trial in patients suffering CDI demonstrated that administration of NTCD-M3 shortly after the use of antibiotics to treat the initial infection successfully reduced recurrence from 30% in placebo to 5% in treated patients. Patients received either vancomycin or metronidazole to treat the initial toxic C. difficile infection before receiving NTCD-M3 treatment.[1] Since the end of this trial, a new antibiotic, fidaxomicin, has been added to US clinical guidelines for treating CDI[2]. It is known that fidaxomicin3 resides for a longer period within the gut potentially inhibiting the colonisation by bacteria such as NTCD-M3. This latest study by the Microbiology Research Laboratory at the Edward Hines, Jr. VA Hospital in the US sought to address this question by monitoring the colonisation of NTCD-M3 in an established CDI model following administration of fidaxomicin. In summary, this study conducted in the lab of the authors at the Edward Hines, Jr. VA Hospital, clearly demonstrated that NTCD-M3 was able to effectively colonise the gut following fidaxomicin administration indicating that NTCD-M3 would be effective in patients receiving this antibiotic as well as older antibiotics such as vancomycin and metronidazole. About Destiny Pharma Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

Join our guests: Neil Clark, Chief Executive Officer, Destiny Pharma PLC and Dale Gerding, MD, FACP, FIDSA, FSHEA with our Guest Host: Kevin Hersh. The robust discussion will touch upon important topics focused on the what, why, and how to Prevent CDI: Boost Immunity, Restore Microbiome, Replace the Bug. Our two guests will exchange a dialogue about the science to answer the many questions about a C. difficile infection, prevention, treatments, what is recurrent C. diff., and the immune system, and how the microbiome plays a part in everything. Tune in and expand you basic knowledge with our guests; Mr. Neil Clark and Doctor Dale Gerding.

Join our guests: Neil Clark, Chief Executive Officer, Destiny Pharma PLC and Dale Gerding, MD, FACP, FIDSA, FSHEA with our Guest Host: Kevin Hersh. The robust discussion will touch upon important topics focused on the what, why, and how to Prevent CDI: Boost Immunity, Restore Microbiome, Replace the Bug. Our two guests will exchange a dialogue about the science to answer the many questions about a C. difficile infection, prevention, treatments, what is recurrent C. diff., and the immune system, and how the microbiome plays a part in everything. Tune in and expand you basic knowledge with our guests; Mr. Neil Clark and Doctor Dale Gerding.

Neil Clark, CEO & Shaun Claydon, CFO of Destiny Pharma #DEST discuss their 2021 highlights including progress of their two, late-stage clinical assets targeted at infection prevention, both of which are backed by strong Phase 2 clinical data and they also outline what's expected in 2022. Operational highlights NTCD-M3 for prevention of C. difficile infection recurrence · Good progress made during the year with the transfer and commencement of manufacturing scale up processes and advancement of discussions with US and European regulators on finalising the detail of the Phase 3 clinical trial design. Regulatory discussions are expected to conclude in the first half of 2022, manufacturing scale up by year-end and the Phase 3 trial is targeted to commence thereafter. · Discussions are progressing with potential licencing partners, with several parties active in the data room. This is in line with the Company's strategy of seeking partners to co-fund Phase 3 trials and lead commercialisation of the asset. · US Department of Veterans Affairs research study confirms the potential of NTCD-M3 as a novel treatment to prevent the recurrence of C. difficile infections (CDI) that can be used alongside all standard-of-care antibiotic treatments. · US and European market research underpins clinical support and market potential of NTCD-M3. · Establishment of a NTCD-M3 clinical advisory board consisting of Professor Dale Gerding MD, US, who discovered NTCD-M3, Professor Mark Wilcox MD, UK key opinion leader in CDI and other medical and drug development experts with recent experience of running and designing international Phase 3 clinical studies in CDI.  XF-73 nasal gel for prevention of post-surgical infections ·       Positive top-line results in Phase 2b clinical study reported in 2021. Primary efficacy endpoint met successfully with high statistical significance and no treatment related safety events.  · Very good secondary endpoint data announced in August 2021 showed that XF-73 has the potential to keep patients at a significantly low S. aureus nasal burden during the period of highest infection risk which runs from 1 hour prior to incision, during surgery itself, to the start of wound healing and out to 6 days post-surgery.  · Independent European report underpins the clinical need and market opportunity of XF-73 nasal gel which is seen as a very promising alternative to the current standard of care, Mupirocin, by both clinicians and payers.   · Successful XF-73 nasal gel Phase 2b study data was presented at 2021 ECCMID (European Congress of Clinical Microbiology & Infectious Diseases) Congress by infection prevention expert, Professor Julie Mangino MD. Earlier pipeline and research projects ·  Two new collaborations signed: NIAID in US supporting XF-73 dermal infection programme and US Department of Veterans Affairs to research NTCD-M3 for prevention of recurrence of CDI. · Pre-clinical work on SporCov COVID-19 programme in collaboration with joint partner SporGen Limited (which is largely funded by an £0.8 million Innovate UK grant) completing in H1 2022. Plans for next stage of development are being progressed.  · XF platform research projects are progressing well after Covid-19 delays and are largely funded by grants and non-dilutive funding. Post period highlights · Positive feedback received from the European Medicines Agency (EMA) on plans for XF-73 nasal gel Phase 3 programme design. Phase 3 can use a similar primary endpoint to the successful Phase 2b clinical study, providing a route through Phase 3 trials to the European approval of XF-73 nasal gel as a ground breaking hospital infection prevention product. Feedback from FDA is expected in Q2 2022.  · Successful completion of the first of two pre-clinical safety studies of XF-73 Dermal formulation. Work continues with US Government's NIAID to complete preclinical safety package that will support future clinical development of XF-73 Dermal in serious wound infections. · China Medical System Holdings Limited (CMS), the Company's China regional partner and investor, started an additional dermal programme with XF-73 targeting the prevention and treatment of superficial skin infections caused by bacteria. · Successful equity fund raise of £6.5 million (gross) to enable continued progress of NTCD-M3 and XF73 nasal toward Phase 3 clinical studies, finalisation of regulatory plans  and strengthening of balance sheet.

Neil Clark, CEO & Shaun Claydon, CFO of Destiny Pharma #DEST discuss how the £6.7m raised will be used to accelerate the development and finalise regulatory plans for the Phase III trials of their two lead key assets: NTCD‐M3 is a potential game-changer for the prevention of C. difficile infection (CDI) recurrence, the leading cause of hospital-acquired infection in the US with a potential peak sales opportunity of $0.5 billion.  XF-73 nasal is being developed for the prevention of post-surgical staphylococcal infections, a $1 billion market opportunity in the US alone.  About Destiny Pharma Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

Neil Clark, CEO & Shaun Claydon, CFO of Destiny Pharma #DEST explain how their funds raised continue progress towards Phase 3 trials in its two lead, clinical assets, NTCD-M3 and XF-73 Nasal, and finalise regulatory plans, whilst also strengthening the balance sheet as the Company progresses partnering discussions in relation to NTCD-M3. Highlights · Placing and Subscription to raise £6.0 million (before expenses) through the issue of 12,000,000 new Ordinary Shares at the Issue Price. · The net proceeds of the Fundraising will allow the Company to continue progress towards Phase 3 trials in its two lead, clinical assets, NTCD-M3 and XF-73 Nasal and finalise regulatory plans, whilst also strengthening the balance sheet as the Company progresses partnering discussions in relation to NTCD-M3. · This Fundraising comes at an important time for Destiny Pharma and the Board decided to proceed in very difficult market conditions because it was felt that any delay in activity on either of the key assets would, in the Board's view, significantly reduce the value of both products and leave the Company in a vulnerable position. · The New Shares, assuming full take-up of the Open Offer, will represent approximately 18.8 per cent. of the Enlarged Share Capital following Admission. · The Issue Price represents a discount of approximately 28 per cent. to the closing mid-market price of 69 pence per existing Ordinary Share on 7 March 2022, being the latest practicable date prior to this Announcement. · Certain of the Directors have conditionally agreed to subscribe for, in aggregate, 140,000 new Ordinary Shares in the Subscription. · A General Meeting to approve the resolutions (the "Resolutions") required to implement the Fundraising is to be held at 11.00 a.m. at the offices of finnCap Limited ("finnCap" or the "Broker"), One Bartholomew Close, London, EC1A 7BL on 28 March 2022 (the "General Meeting"). A detailed timetable of events is set out in Appendix I of this Announcement. About Destiny Pharma Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SporCov, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects. 

In this one part #BettingPeople special, author Neil Clark talks about his new book 'Champion Jump Horse Racing Jockeys from 1945 to Present Day. He describes his background and why he decided to write this book which encompasses some lesser known Champion Jump Jockeys as well as the more recent. He talks about his three favourite Champs and their fascinating stories. Meeting Neil Clark.

Neil told us about his career starting out at Portsoy ,playing in the men's league as a youngster then moving on to Cummieston juniors then trials at Dundee Utd then signing for Utd ,Moving back to junior football before joking Fraserburgh in the highland league and took us through the rest of his career --- Send in a voice message: https://anchor.fm/willie474/message

How do human factors influence an inherently risky activity like scuba diving?That's what my guest on this episode, Gareth Lock explores in his work as the founder of The Human Diver — a company that specialises in teaching the diving community about human factors.Whether you've ever been diving or not, it's fairly obvious that it's an activity, that comes with a degree of inherent risk. After all, It involves getting into an environment that requires us to use specialist equipment because being underwater impacts our ability to breathe naturally and diminishes the use of some of our senses. It also exposes us to some potentially dangerous conditions - temperature, currents and air pressure for starters. Not to mention the sea creatures we might come across, who aren't necessarily always going to welcome our intrusion into their world.As Gareth explains in our discussion, those dynamics can be made far worse by humans. Most accidents and incidents in diving arent down to technical failures, rather they are down to complacency, breakdowns in communication, poor decision-making, a lack of situational awareness or ineffective teamwork and/or leadership.To find out more about:Gareth - https://www.thehumandiver.com/theteamThe Human Diver - https://www.thehumandiver.com/Under Pressure, Gareth's book - https://www.thehumandiver.com/underpressure

The Human Factors in Diving Conference - https://www.hf-in-diving-conference.com/In our discussion, we also refer to Tim Harford. You can hear the episode of this podcast featuring Tim here: https://www.podpage.com/the-human-risk-podcast/tim-harford-on-using-data-to-make-smarter-decisions/Listeners interested in hearing more about Human Factors will enjoy this episode of the show featuring Neil Clark: https://www.humanriskpodcast.com/neil-clark-on-human-factors/

Join our guests: Neil Clark, Chief Executive Officer, Destiny Pharma PLC and Dale Gerding, MD, FACP, FIDSA, FSHEA with our Guest Host: Kevin Hersh. The robust discussion will touch upon important topics focused on the what, why, and how to Prevent CDI: Boost Immunity, Restore Microbiome, Replace the Bug. Our two guests will exchange a dialogue about the science to answer the many questions about a C. difficile infection, prevention, treatments, what is recurrent C. diff., and the immune system, and how the microbiome plays a part in everything. Tune in and expand you basic knowledge with our guests; Mr. Neil Clark and Doctor Dale Gerding.

Join our guests: Neil Clark, Chief Executive Officer, Destiny Pharma PLC and Dale Gerding, MD, FACP, FIDSA, FSHEA with our Guest Host: Kevin Hersh. The robust discussion will touch upon important topics focused on the what, why, and how to Prevent CDI: Boost Immunity, Restore Microbiome, Replace the Bug. Our two guests will exchange a dialogue about the science to answer the many questions about a C. difficile infection, prevention, treatments, what is recurrent C. diff., and the immune system, and how the microbiome plays a part in everything. Tune in and expand you basic knowledge with our guests; Mr. Neil Clark and Doctor Dale Gerding.

Join our guests: Neil Clark, Chief Executive Officer, Destiny Pharma PLC and Dale Gerding, MD, FACP, FIDSA, FSHEA with our Guest Host: Kevin Hersh. The robust discussion will touch upon important topics focused on the what, why, and how to Prevent CDI: Boost Immunity, Restore Microbiome, Replace the Bug. Our two guests will exchange a dialogue about the science to answer the many questions about a C. difficile infection, prevention, treatments, what is recurrent C. diff., and the immune system, and how the microbiome plays a part in everything. Tune in and expand you basic knowledge with our guests; Mr. Neil Clark and Doctor Dale Gerding.

But he wipes out legal fund for legislators looking to hire private lawyers in gerrymandering cases, ‘The companies drove the bus': Neil Clark's book details his views on House Bill 6, FirstEnergy and what he told FBI agents, Ohio congressional candidate Max Miller's tax records show he claims his principal residence is in Washington, D.C., City of Akron required to turn in body camera surveillance if an officer uses deadly force or causes bodily harm and Judicial party ID bill, school report card overhaul among 13 bills signed by Ohio Gov. Mike DeWine. See acast.com/privacy for privacy and opt-out information.

Alexander Mercouris, host of "The Alexander Mercouris Show" on YouTube, joins us to discuss the latest news regarding Ukraine. Ukrainian president Vladimir Zelensky met with notorious anti-Russian leaders of the Baltic states to sign a joint declaration of cooperation. Zelensky went on to refer to the Russian annexation of Crimea as "war in Europe," ignoring the referendum in which the citizens of Crimea chose Russia over the US client state of Ukraine.Dr. Jack Rasmus, professor in the economics and politics departments at St. Mary's College of California, joins us to discuss the economy. Dr. Jack looks into the current economic upswing and examines whether the dynamics that created it are enough to support long-term recovery.Neil Clark, journalist and broadcaster, joins us to discuss Julian Assange. Whistleblower Edward Snowden argues that President Biden's claim of supporting World Press Freedom Day rings hollow as he pursues Julian Assange. “This would be more persuasive if the White House weren't aggressively seeking a 175-year sentence for the publisher of award-winning journalism of global importance – despite pleas from every significant press freedom and human rights organization,” Snowden tweeted.K. J. Noh, peace activist, writer and teacher, joins us to discuss China. The Trump administration removed an Islamist jihadist Uyghur group from the official list of terrorist organizations. The group was involved in high-profile attacks in China. Now, the DC neocons are ignoring the group's history and seem to be enlisting them in the asymmetric war on China.Dan Lazare, investigative journalist and author of "America's Undeclared War," joins us to discuss US-Russia relations. An article in The National Interest points out several points that President Biden needs to hit to soothe relations between the two nuclear superpowers. Julie Hurwitz, civil rights attorney and partner at the law firm Goodman, Hurwitz and James, joins us to talk about the Flint, Michigan-water crisis. The prosecution of the Flint crisis is underway, as we discuss the parties involved and the hurdles that will be presented in the effort to prosecute the defendants. Robert Fantina, journalist and Palestine activist, joins us to discuss Israel. Our guest joins us to discuss the Human Rights Watch report that labels the Israeli occupation of Palestine as apartheid. Also, we discuss the international definition of apartheid and whether it should apply.Laith Marouf, broadcaster and journalist based in Beirut, Lebanon, joins us to discuss Yemen. President Biden claimed that he was going in a different direction on Yemen, but is still supporting the Saudi-led war. Also, the Yemen military has been having success against the Saudi Kingdom using accurate military drones laden with explosives.

Dan Lazare, investigative journalist, author of "America's Undeclared War," joins us to discuss the CIA. Lee Camp's latest article reviews the recent Director of National Intelligence report, and argues that it is a perfect example of how the CIA and its sister agencies have gotten out of control. Camp recalls historical evidence of former US heads of state long ago, warning that this eventuality would be destructive for the nation.Neil Clark, journalist and broadcaster, joins us to discuss Julian Assange. A recent report demonstrates that the UK government played an integral part in the extraction of Julian Assange from the Ecuadorian Embassy. Also, the UN Special Rapporteur on Torture, Nils Melzer, has a new book in which he raises serious allegations about powerful interests manipulating the justice system.Elisabeth Myers, lawyer, former editor-in-chief of Inside Arabia and democracy lead for Democrats Abroad, joins us to discuss Yemen. The Biden administration has admitted that they are still maintaining the Saudi air force. This seems to contradict earlier statements which implied that they intended to ease up support for the genocidal war against the impoverished nation of Yemen.Ted Rall, political cartoonist and syndicated columnist, joins us to discuss propaganda in the US media. CNN is getting intense pushback for hiring Natasha Bertrand. Opponents argue that Bertrand has little credibility as a journalist, but is extremely useful for pushing unsubstantiated propaganda from the intelligence community. Bertrand has been repeatedly panned for playing fast and loose with the facts regarding the infamous "Steele dossier."Netfa Freeman, host of Voices With Vision on WPFW 89.3 FM, Pan-Africanist and internationalist organizer, joins us to discuss President Biden's infrastructure plan and the US moves to restrict African nations' access to Chinese investment. The US is warning African nations against doing business with China in a move that smacks of colonialism and economic arm twisting. Also, President Biden's infrastructure plan is being pushed as a counter to China rather than a needed upgrade for America.Medea Benjamin, co-founder of Code Pink, joins us to discuss Iran. As the Iran nuclear agreement negotiations seem to drift aimlessly, US National Security Adviser and noted neocon Jake Sullivan has been meeting with Israeli representatives to keep them apprised of the status of the deal. Also, Code Pink argues that little has changed in US foreign policy after President Biden assumed power.Dr. Jack Rasmus, professor in the economics and politics departments at St. Mary's College of California, joins us to discuss the economy. Our esteemed guest discusses President Biden's proposed "American Families Plan." This plan includes increases in taxes for the wealthiest of Americans and would directly follow the infrastructure plan.Gary Flowers, host of “The Gary Flowers Show” on radio station Rejoice WREJ-AM 990, joins us to discuss police killings in the US. A group of human rights experts are calling on the International Criminal Court in the Hague to investigate US police killings against Black Americans as a crime against humanity. The move to take the US government to the international court regarding the treatment of Black Americans recalls the legacy of William L. Patterson and Paul Robeson's 1951 "We Charge Genocide" petition to the UN.

Scott Ritter, the former UN weapon inspector in Iraq, joins us to discuss Iran. Tehran and Washington remain in a standoff as the Biden administration maintains Trump policies on the JCPOA. Also, Israeli defense minister Benny Gantz has stated that the US will be working very closely in coordination with Israel regarding the policies and terms for reentry into the nuclear agreement. It is widely known that Israel rejects the basic concepts of the agreement, and regards a military engagement as a more welcome outcome. Gerald Horne, professor of history at the University of Houston, author, historian, and researcher, joins us to discuss the latest police shooting in Minneapolis, Minnesota. A Black man was shot by police after being stopped for dangling air fresheners in his vehicle. Police report that the victim had an outstanding warrant, but they have released no information on the nature of the warrant or exactly why the officer used deadly force.Alexander Mercouris, host of "The Alexander Mercouris Channel" on Youtube, joins us to discuss the latest news on Ukraine and the Nordstream 2 pipeline project. Turkish Prime Minister Recep Erdogan met with Ukrainian leader Vladimir Zelensky regarding the tense situation on the Russian border. Erdogan backed the NATO position, and called for the return of Crimea to the Eastern European US vassal state of Ukraine. Neil Clark, journalist and broadcaster, joins us to discuss Julian Assange. Advocates for press freedom marked the two year anniversary of Julian Assange's arrest on Sunday with demands that the Biden administration drop all charges against the imprisoned publisher. They condemned Assange's arrest and threats against the beleaguered publisher of up to 175 years in prison as a threat to freedom of the press worldwide.Dan Lazare, investigative journalist, author of "America's Undeclared War," joins us to discuss the Biden administration's increased threats towards Russia and China. US Secretary of State Antony Blinken was interviewed by NBC's Chuck Todd, in what turned out to be an orgy of animus towards the two nuclear superpowers. Todd repeatedly challenged Blinken to be more hawkish and at times seemed to imply that military action is in order.Ted Rall, political cartoonist and syndicated columnist, joins us to discuss President Biden's military budget request. Activists and some members of Congress are furious over the proposed military budget increase by the Biden administration. They are arguing that the administration's priorities are mixed up, as the pandemic has crushed the nation's economy and the latest round of covid relief provided a meager one time payment to some struggling Americans.Marvin Weinbaum, director for the Middle East Institute's Center for Pakistan and Afghanistan Studies, joins us to discuss Afghanistan. There are reports that Turkey is working with the US to prolong the US occupation of Afghanistan. Also, peace prospects are stalling, as the Taliban feels that they have the upper hand militarily and the current Afghan ruling elite work to maintain power when, and if, the US abandons it's occupation.Ajamu Baraka, former VP candidate for the Green Party, joins us to discuss the Global South. Peru and Ecuador held elections and the results showed promise for a growing anti-imperialist movement in South America. Also, the Biden administration is following in the footsteps of the Trump team by supporting the brutal dictatorial regime of Jovenel Moise in Haiti.

Scott Ritter, former UN weapon inspector in Iraq, joins us to discuss Iran. The signatories of the Iran nuclear deal met in Vienna on Tuesday, and there are signals that the US is considering a return to the agreement. Also, Israel is voicing its fury at the prospect of a renewed deal, and are suspected to be involved in attacks on Iranian merchant marine vessels.Neil Clark, journalist and broadcaster, joins us to discuss Julian Assange. Eleven years after Wikileaks released the collateral murder video which documented US war crimes in Iraq, the publisher of the information languishes in Belmarsh prison and the perpetrators walk free. Also, Caitlin Johnstone writes that the persecution of Julian Assange exposes the West's moral high ground claims as fraudulent and hypocritical.Ted Rall, political cartoonist and syndicated columnist, joins us to discuss domestic politics. The Senate parliamentarian has ruled that the upper chamber may use the reconciliation process at least two more times this year. This allows the ruling party to bypass the filibuster and pass legislation with a simple majority. This process may be used to pass both infrastructure and tax reform bills with no republican votes. Dan Lazare, investigative journalist and author of "America's Undeclared War," joins us to discuss the Nordstream 2 pipeline project. Germany is caught in an international tug of war as they fight the Biden administration over their right to self-determination. Recently, anti-Russian forces in the US and EU have upped the ante as they have started sending ships and submarines to disrupt Germany's energy infrastructure plan. Many suspect that the US is interfering in German politics and supporting the Green party.Dr. Iyabo Obasanjo, professor at College of William & Mary and daughter of former Nigerian President Olusegun Obasanjo, joins us to discuss the latest coronavirus news. Five US states, New York, Michigan, Florida, Pennsylvania and New Jersey, are currently accounting for 44% of new covid positive cases in the last week. Also, the issue of vaccine passports is emerging as the next partisan divide in the US.Mark Sleboda, Moscow-based international relations security analyst, joins us to discuss Ukraine. The Eastern European nation has plunged the continent into a tense standoff by threatening war with Russia. Many are comparing Ukrainian president Vladimir Zelensky's ham-fisted military maneuvers with those of Georgian politician Mikheil Saakashvili, who led his nation into a disastrous confrontation with Russia in South Ossetia.James Carey, editor/co-owner of Geopoliticsalert.com, joins us to discuss Afghanistan. President Biden is not revealing whether he will pull the troops from Afghanistan before the May 1st deadline agreed upon in previous negotiations. Many international security analysts point to his hawkishness and militaristic Secretary of State Antony Blinken as an indicator that he will most likely continue, and possibly intensify the twenty-year conflict. Dan Kovalik, writer, author, and lawyer, joins us to discuss Haiti. In his latest article, Berthony Dupont argues that "our country has been and still is the victim of what must be called the war of American imperialism against Haiti." He believes that the nation is "sinking into violence and institutional crisis" that was established by the former colonial powers of America, France, and Canada.

President Biden inadvertently pushed Germany into a fight against imperialism when he attacked Berlin's eleven billion dollar pipeline project with Russia.John Burris, civil rights attorney, joins us at the opening of the George Floyd trial. Derek Chavin, the Minnesota police officer charged in the killing of George Floyd, faces a criminal proceeding that will draw attention worldwide. Judge Peter Cahill started the trial by hearing a preliminary motion about what lawyers can say about George Floyd's state of mind during the arrest.Neil Clark, journalist and broadcaster, joins us to discuss Julian Assange. Stella Morris, Julian Assange's partner and the mother of his children, revealed that the Pope sent a private message to the beleaguered journalist. She would not reveal the contents of the message but thanked him for his concern. Also, there are reports from London that his legal team will be filing a special appeal today. Daryl Jenkins, retired Chief Engineer in the Merchant Marine and a current fleet maintenance manager in the industry, joins us to discuss the shipping crisis in the Suez Canal. There has been some movement made in the attempt to refloat a ship that is blocking the Suez Canal. Shipping experts estimate that there are approximately 10 billion dollars in trade each day. As a result, many shippers are starting to consider alternative routes in case the canal is disrupted again. Kevin Gosztola, the managing editor of Shadowproof.com, joins us to discuss internet censorship. Congress called in the heads of the US social media giants last Thursday and grilled them over the issue of online censorship. They argued for increased censorship, and argued that the January 6th capitol protest was an example of why further crackdowns are needed. Also, Facebook has frozen the account of Iran's Press TV.Dan Lazare, investigative journalist and author of "The Velvet Coup: The Constitution, the Supreme Court and the Decline of American Democracy," joins us to discuss the Nordstream 2 pipeline. The fight between Germany and the US over the Nordstream 2 pipeline is really a battle over national sovereignty and imperialism. The US has inadvertently pushed Germany to join Russia in an anti-imperialist battle against US hegemony. The Biden team and the US Congress argue that they have the right and the political might to force Germany and, by proxy, any other European nation to bow to their whims.KJ Noh, peace activist, writer and teacher, joins us to discuss the strategic partnership between China and Iran. The two nations have signed a historic 25-year deal that international experts have estimated could easily top a half-trillion dollars. China's entry into Middle Eastern affairs is a game-changer, and will likely affect America's ability to use violence and coercive measures to execute their foreign policy.Netfa Freeman, host of Voices With Vision on WPFW 89.3 FM, Pan-Africanist and internationalist organizer, joins us to discuss the global south. Brazilian politician Lula De Silva has been cleared of the illegal plot which was used to remove him from contention for the nation's presidency during the last election process. The 74-year-old politician is extremely popular and, in light of the disastrous coronavirus response from the Bolsonaro regime, may have a chance of gaining the top spot.Dr. Gerald Horne, professor of history at the University of Houston, author, historian, and researcher, joins us to discuss Amazon employees' fight for union membership. The fight for unionization at the Bessemer, Alabama location has grand implications as workers nationwide await the outcome. There are reports that Amazon owner Jeff Bezos is pushing his executives to fight the process, as he fears that the move for employee representation will spread.

Neil Clark, journalist and broadcaster, joins us to discuss the anniversary of the US invasion of Iraq. Anti-war activists argue that the US should pay reparations to the people of Iraq after nearly two decades of misery and death set upon them by an illegal war. Also, ten years ago Julian Assange and WikiLeaks infuriated the US empire and its vassal states by releasing details of war crimes in Iraq. Today, Assange pays the price for exposing the moral decadence of US imperialism.Dr. Iyabo Obasanjo, professor at College of William and Mary and daughter of former Nigerian President Olusegun Obasanjo, joins us to discuss the coronavirus. The US is reopening fully as stimulus checks arrive, and the roads and stores are packed with spring shoppers. Also, the AstraZeneca vaccine is shown to have about 79% effectiveness against the coronavirus as investigations into the possibility of complications with blood clots continue. Scott Ritter, former UN weapon inspector in Iraq, joins us to discuss his latest articles on President Biden's insults towards Russian President Vladimir Putin. Ritter argues that the international debacle of insulting a head of state would be laughable if the potential consequences were not so dire. Also, Ritter posits that US Secretary of State Tony Blinken's verbal assault on China's diplomats will surely backfire.Dr. Gerald Horne, professor of history at the University of Houston, author, historian, and researcher, joins us to discuss the Biden administration's week of major foreign policy bungles. The Biden administration has alarmed both allies and adversaries alike, as they have threatened sanctions against Germany, India, Russia and China in the space of 72 hours. The buster and bravado may be playing well amongst the Washington neocon punditry, but none of the moves appears to be consistent with Biden's stated foreign policy objectives.Caleb Maupin, journalist and political analyst, joins us to discuss the strategic alliance between Russia and China. The alliance between military superpower Russia and economic superpower China is growing in response to the unhinged aggressive policies of the Washington, DC-foreign policy consensus. Also, North Korea is refusing dialogue with US diplomats because of their harsh aggressive tone, and China is stating that they are ready to step in and preside over peace on the Korean peninsula.Ted Rall, a political cartoonist and syndicated columnist, joins us to discuss the influence of dark money in US elections. Alan Macleod's latest Mintpress article argues that the billion dollars of domestic dark money that the ultra-wealthy and major corporations spent on the 2020 elections are treated as business as usual by the US media while they push evidence-free conspiracy theories about the influence of memes on Facebook. Joe Lauria, editor-in-chief at Consortium News, joins us to talk about the never-ending saga of "Russia-gate." In his latest article, Lauria argues that "when it comes to national security reporting, corporate journalists have time and again shown they are practicing something other than journalism." He goes on to illustrate how the latest US intelligence assessment gives cover for President Joe Biden to continue the absurd aggressive confrontation. Also, US entanglement in endless wars and internal instability have convinced the Chinese that Western-style democracy is not as attractive as their socialist alternative. KJ Noh, peace activist, writer and teacher, joins us to discuss China. A series of spectacular stumbles including the 2008 economic crash and a bungled response has demonstrated to China that America's financial system is a paper tiger. Also, US entanglement in endless wars and internal instability have convinced the Chinese that Western style-democracy is not as attractive as their socialist alternative.

“Super-lobbyist” Neil Clark, a key figure in the $60 million Statehouse nuclear bailout scandal, was found dead near his home in Florida last week.

“Super-lobbyist” Neil Clark, a key figure in the $60 million Statehouse nuclear bailout scandal, was found dead near his home in Florida last week. Two days after Clark's death was discoered, Ohio House Republicans declined to vote on whether to expel his racketeering co-defendant, former House Speaker Larry Householder.

“Super-lobbyist” Neil Clark, a key figure in the $60 million Statehouse nuclear bailout scandal, was found dead near his home in Florida last week. Two days after Clark's death was discoered, Ohio House Republicans declined to vote on whether to expel his racketeering co-defendant, former House Speaker Larry Householder.

In this week's episode of Snollygoster, Ohio's politics podcast from WOSU, hosts Mike Thompson and Steve Brown discuss the political legacy of Neil Clark, a powerful lobbyist and a defendant in the $60 million nuclear plant bribery case, who was found dead this week in Florida.

Lloyd Cole and the Commotions special with Neil Clark  in conversation with David Eastaugh Scottish guitarist, known for his work with Lloyd Cole and the Commotions. He has regularly worked and toured with Lloyd Cole post-Commotions including playing on and touring in support of Cole's 2006 album, Antidepressant. He also worked on Cole's albums, Bad Vibes, Love Story, Etc, Music in a Foreign Language and Guesswork. Clark was a member of Bloomsday with Stephen Irvine of the Commotions and Chris Thomson of The Bathers. Clark also features on the Bathers' 1993 album, Lagoon Bluesand has collaborated with Canadian singer Mae Moore on her album Dragonfly. His guitar playing was featured on her single from that album "Genuine", which reached No. 6 on the RPM "Top 100" singles chart in Canada. In 1995 and 1998 he worked on two albums with French singer Axelle Renoir. Has released two solo albums, Sundogs in 2008 and Second Story Sunlight in 2010. Both albums mix minimalist and cinematic guitar styles with ambient electronica. He currently also plays and writes with Ambrose Pottie, (drums) and Alisdair Jones (bass) in post-jazz trio, Sleepers.

By months end, every Ohioan 16 or over will be eligible for coronavirus vaccinations. A good government group in Ohio wants lobbyists to disclose sources when fundraising for politicians. Ohio's vaccine registration site turned a lot of people into fibbers. ACLU data analysis prompts years overdue Bail reform in Ohio. Neil Clark found dead with a head wound and a handgun near his home in Florida. See acast.com/privacy for privacy and opt-out information.

March 16, 2021: When all Ohioans will be eligible for COVID vaccines as the state’s first mass vaccination site starts seeing people, when to expect your stimulus check, what to do if you already filed your 2020 taxes and you overpaid on unemployment benefits, FirstEnergy board of directors moves and more on 3News Now with Stephanie Haney. Like this show? Check out the 3 Things to Know with Stephanie Haney podcast: http://wkyc.com/3thingstoknow Connect with Stephanie here: http://twitter.com/_StephanieHaney http://instagram.com/_StephanieHaney http://facebook.com/thestephaniehaney Read more here: (0:20) All Ohioans 16 and older to be eligible for COVID-19 vaccines starting March 29. https://www.wkyc.com/article/news/health/coronavirus/vaccine/ohio-covid-19-vaccine-eligibility-expands-to-all-ohioans/95-f21755f3-d8fe-4e58-a624-dd9916b2fa42 (1:55) Live blog: Mass COVID-19 vaccinations to begin at Cleveland's Wolstein Center. https://www.wkyc.com/article/news/health/coronavirus/vaccine/ohio-mass-covid-19-vaccinations-wolstein-center-cleveland/95-d24da137-73c3-42b2-8830-ff451911f34f (3:17) Tens of millions should get stimulus checks Wednesday, banking groups say. https://www.wkyc.com/article/news/health/coronavirus/third-stimulus-check-1400-details/507-bd5fb0bc-6e2f-42b4-a4b3-55405b3d063f (5:33) The latest on the number of COVID-19 cases in Ohio. https://www.wkyc.com/article/news/health/coronavirus/coronavirus-ohio-updates/95-e2faeb56-d02a-443a-bcdb-141f2c7fafe8 https://www.wkyc.com/article/news/health/coronavirus/timeline-of-coronavirus-cases-ohio/95-c97c228d-c6c7-4949-b12b-4324d7ed8bb5 (6:49) New IRS waiver impacts unemployment income. https://www.wkyc.com/article/money/new-waiver-impacts-unemployment-income-internal-revenue-service/95-592c6f4f-e3eb-4b25-b89b-b069c87147be (8:01) Report: FirstEnergy nearing deal to give billionaire Carl Icahn two seats on company's board. https://www.wkyc.com/article/news/local/akron/report-firstenergy-nearing-deal-carl-icahn-two-seats-company-board/95-770c7c1a-4ee9-4950-8e41-e0aa10bf6c46 (10:00) Neil Clark, lobbyist named in $60 million Ohio bribery probe, found dead in Florida. https://www.wkyc.com/article/news/local/ohio/neil-clark-lobbyist-named-60-million-ohio-bribery-probe-found-dead-florida/95-58fc40d3-6e4d-4049-8ee5-2bc72629c31e (11:00) Ford plans to move new project from Avon Lake plant to Mexico. https://www.wkyc.com/article/news/local/lorain-county/ford-plans-move-new-project-from-avon-lake-to-mexico/95-f5f0aa72-e30e-4f01-b32a-2d033907bd11 (12:29) Cleveland Browns earn rave reviews for signing of John Johnson III https://www.wkyc.com/article/sports/nfl/browns/browns-john-johnson-iii-reviews/95-553b0cef-251f-40f0-b1b4-5602ff2fbc53 (12:40) Report: Cleveland Browns sign DE Takkarist McKinley to 1-year deal. https://www.wkyc.com/article/sports/nfl/browns/report-cleveland-browns-sign-de-takkarist-mckinley-to-1-year-deal/95-79510f2a-d453-42c5-b02b-f877866a50c1

Hat der britische Paläontologe Neil Clark etwa das Rätsel um Nessie gelöst? Der Forscher ist den Berichten über das 'Monster' auf den Grund gegangen und dabei auf einen Wanderzirkus gestoßen, der 1933 auch in Loch Ness Station gemacht haben soll.

Laura Besley is a writer of short and super-short fiction. Josh Corson is a poet and educator usually playing guitar or PlayStation instead of writing. Ankita Sharma is a writer and artist based in India and has authored four titles. Neil Clark writes tiny stories from his tiny flat in Edinburgh, Scotland, and has releasedContinue reading "Besley x Corson x Sharma x Clark" Learn more about your ad choices. Visit megaphone.fm/adchoices